20090506
 Corporate News: Biovail Slashes Dividend, Buys U.S. Rights to Wellbutrin   By Georgiades, Andy; King, Carolyn, The Wall Street Journal,  May 7, 2009  Biovail Chief Executive Bill Wells said the Wellbutrin deal, which brings substantial cash flow, has no other purpose than accelerating Biovail's entry into specialty neurology -- a prospect that would appeal to growth investors.   
